Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146328 · ClinicalTrials.gov registry record · Phase 2
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 997
- Enrollment target
NCT00146328: Completed Phase 2 study, sponsored by Boehringer Ingelheim.
NCT00146328 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 997 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (650% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00146328, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 997 participants
- Enrollment target
Study Summary
The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.
Primary Outcome
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Interventions
- DRUG Tipranavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 997 participants |
| Start Date | 2001-04 |
| Phase | Phase 2 |
What the finished NCT00146328 record still lists
NCT00146328 is an interventional study that assigns participants to a tested intervention. The registered 997 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (650% higher).
The record links to 0 conditions, and to 1 intervention - of which Tipranavir is the first listed.
NCT00146328 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00146328 about?
NCT00146328 is a clinical study titled "Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects". The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications...
What is the current status of trial NCT00146328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 997 participants. The study started on 2001-04.
What interventions are being tested in trial NCT00146328?
The interventions under investigation include: Tipranavir (DRUG).
Who is sponsoring clinical trial NCT00146328?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00146328's enrollment target sits among peer trials
997 26th of 2000 higher than 1,975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005024 · 996 participants · Phase 3
DOAC - Dosing Options in AntiCoagulation Prophylaxis
- NCT02986048 · 999 participants
Proton Therapy Patient Registry
- NCT04703244 · 999 participants
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia